Brand-Name Drug Makers Win Key Provisions In Central American Free-Trade Pact

Law360, New York (July 4, 2005, 12:00 AM EDT) -- U.S. brand-name drug makers appear to have scored a major victory with the pharmaceutical provisions of the Central American Free Trade Agreement, which would provide five years of market exclusivity to new drugs.

The requirement gives brand-name manufacturers market exclusivity for five years after a drug is registered in the countries covered by the agreement, even if the 20-year patent has expired.

A similar five-year period exists in the U.S., but the trade agreement would require countries to enforce the five-year period even if the exclusivity...
To view the full article, register now.